ACRS = MC $44 M / Cash $115 M/ Phase 3 readout imminent Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ACRS = MC $44 M / Cash $115 M/ Phase 3 readout imminent

ACRS 2.425

+3.6%

2:46 PM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

From: BioHero	10/7/2019 9:22:02 AM
	of 23

Price $1.13 ...Market cap $45 Million ...Cash $115Million ...Book Value $3.30 ...Cash per Share $2.79 = MEGA STRONG BUY UPCOMING BIG MILESTONES EXPECTED DURING Q4 Eskata approval could come this or next Week A-101(common warts) final Phase 3 readout within 4-6 weeks ATI-450 (Rheumatoid arthritis) Phase 1 results before year end Partnership(s) for Eskata (approved), Rhofade (approved), A-101 (Phase 3) , ATI-502 (Phase 2) oral & topical could hit the wire anytime now .

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next